Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | GMPS | P49915 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 3/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL20702110 | 0.96 | SLC28A1 (0.46) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL29817041 | 0.91 | SLC28A1 (0.45) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL8714851 | 0.88 | ADORA2A (0.44) | SLC28A1ADORA3ADORA2AGMPSPI4KA | |
| SCHEMBL27730982 | 0.87 | SLC28A1 (0.49) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL6513203 | 0.86 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2AGMPSPI4KA | |
| SCHEMBL29812366 | 0.86 | ADORA1 (0.44) | SLC28A1ADORA3ADORA2AEGFRADORA1 | |
| SCHEMBL29720399 | 0.85 | ADORA1 (0.40) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL15875792 | 0.85 | SLC28A1 (0.53) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL8576963 | 0.84 | ADORA2A (0.41) | SLC28A1ADORA3ADORA2AEGFRGMPS | |
| SCHEMBL8058704 | 0.84 | SLC28A1 (0.52) | SLC28A1ADORA3ADORA2AEGFRGMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | claimed |
| EP-0548189-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE. | STERLING WINTHROP INC (US) | 1993-06-30 | — | — | EP | claimed |
| WO-1992004364-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260028368-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | INTEGRATED DNA TECH INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12459968-B2 | Oligonucleotide synthesis on solid support | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4413130-A1 | NUCLEIC ACIDS CONTAINING ABASIC NUCLEOSIDES | E-Therapeutics plc (GB) | 2024-08-14 | — | — | EP | disclosed |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-04 | — | — | US | disclosed |
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | disclosed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995031470-A2 | ANTISENSE INHIBITORS OF GENE EXPRESSION | MERCK FROSST CANADA INC. (CA) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0202758-A1 | Hybridization method and probes therefor | ZENECA LIMITED (GB) | 1986-11-26 | — | — | EP | disclosed |
| EP-0058954-A2 | Tridecadeoxynucleotide, process for its preparation and the application | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | SLC28A1 931/4885ADORA3 3497/4885ADORA2A 2915/4885 |
| US-20260028368-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | NSUN2, RNGTT, POLR2H | SLC28A1 671/4885ADORA3 1594/4885ADORA2A 2177/4885 |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | SLC28A1 931/4885ADORA3 3497/4885ADORA2A 2915/4885 |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | SLC28A1 931/4885ADORA3 3497/4885ADORA2A 2915/4885 |
| US-12459968-B2 | Oligonucleotide synthesis on solid support | RNGTT, SSU72, NSUN2 | SLC28A1 400/4885ADORA3 1988/4885ADORA2A 1656/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | SLC28A1 631/4885ADORA3 2462/4885ADORA2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.